News and Trends 9 Feb 2023 Cell and Gene Therapy Catapult boost for life science campus The Cell and Gene Therapy Catapult (CGT Catapult), an independent U.K. innovation and technology organization specializing in the advancement of cell and gene therapies, has announced its involvement in the development of a major new campus for life science businesses in Stevenage. The new campus was announced by UBS Asset Management’s Real Estate & Private […] February 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Sanofi and GSK Covid-19 booster vaccine approved by European Commission Sanofi and GSK’s Covid booster vaccine has been approved in Europe. After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, the vaccine was approved by the European Commission, as a booster for the prevention of Covid-19 in adults 18 years of age and older. […] November 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment A global collaboration was announced today (August 9) between Mersana Therapeutics Inc and GSK plc that will give GSK the option to co-develop and commercialize an antibody drug conjugate (ADC). The ADC called XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells. Anna […] August 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2022 GSK positive on RSV vaccine for older adults GSK plc has announced positive headline results from its AReSVi 006 phase III trial. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. GSK said no unexpected safety concerns were observed. Dr Hal Barron, chief scientific officer and president, R&D, GSK, said, […] June 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2022 Upstream Bio to target asthma as it launches with $200M financing Upstream Bio, a U.S. biotech company focused on inflammation, today exited stealth mode with $200M Series A financing. The company said the funding will allow it to advance its lead program UPB-101, a clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. It added the investment will also help build a pipeline of assets […] June 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2022 GSK to acquire clinical-stage biopharmaceutical company Affinivax GSK plc is set to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1B upfront payment and up to $1.2B in potential development milestones. Affinivax is developing a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and […] June 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2021 GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […] June 30, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2021 GSK Acne Deal Heralds Growing Interest in Skin Microbiome This week, the Paris-based Eligo Bioscience became one of a growing number of biotechs to land a big pharma deal focused on the skin microbiome, receiving up to €185M from GlaxoSmithKline (GSK) as they explore a CRISPR-based treatment for acne. Acne is a condition that troubles the majority of adolescents and often persists into adulthood. […] January 15, 2021 - 4 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jul 2020 Pharma Giant GSK and mRNA Biotech CureVac Ink €1B Deal GlaxoSmithKline (GSK) has struck a deal worth up to €1B with the German biotechnology company CureVac to co-develop messenger RNA drugs for infectious diseases. Under the terms of the deal, GSK will fund the development and manufacturing of up to five mRNA-based vaccines and antibody drugs targeting undisclosed infectious diseases. CureVac’s current rabies and Covid-19 […] July 23, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2020 ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada A monthly two-drug injection developed by the GSK spinoff ViiV Healthcare has been approved for the treatment of HIV in Canada, which could replace the need for daily antiretroviral pills. The treatment — branded as Cabenuva and developed in collaboration with Janssen — was approved by Health Canada to suppress HIV in adults with stable […] March 23, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Feb 2020 Update: Janssen and Maze Jump on Board Finnish Genomics Project Update (25/02/2020): Janssen and the US company Maze Therapeutics are the latest pharma companies to sign up as partners in the public-private genomics collaboration FinnGen. FinnGen’s pharma partners now total 11, including Sanofi and GSK, which joined early last year. Published 23/01/2019: Sanofi and GSK have joined up with a project collecting genomic and health […] February 25, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2020 Immatics Partners GSK in Deal Worth €1B to Develop Cancer Therapies The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive […] February 20, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email